| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|---|---|---|---|---|---|---|
Net revenues | |||||||
322,357 | 294,666 | 240,175 | 255,165 | 251,519 | 210,461 | 229,681 | 204,323 |
Cost of revenues | |||||||
190,434 | 187,681 | 149,666 | 150,969 | 174,172 | 159,205 | 142,725 | 114,020 |
Gross profit | |||||||
131,923 | 106,985 | 90,509 | 104,196 | 77,347 | 51,256 | 86,956 | 90,303 |
Operating (income) expenses: | |||||||
Selling, distribution, and marketing | |||||||
12,830 | 8,156 | 6,460 | 5,466 | 5,470 | 5,564 | 5,349 | 4,426 |
General and administrative | |||||||
50,279 | 49,888 | 44,458 | 41,832 | 41,504 | 34,809 | 30,972 | 27,223 |
Research and development | |||||||
68,853 | 57,564 | 43,503 | 41,522 | 37,271 | 28,866 | 33,019 | 31,163 |
Gain on sale of intangible assets | |||||||
- | - | 2,643 | - | - | - | - | - |
Impairment of long-lived assets | |||||||
- | - | - | - | - | - | 126 | 2,094 |
Total operating expenses | |||||||
131,962 | 115,608 | 91,778 | 88,820 | 84,245 | 69,239 | 69,466 | 64,906 |
Income (loss) from operations | |||||||
-39 | -8,623 | -1,269 | 15,376 | -6,898 | -17,983 | 17,490 | 25,397 |
Non-operating (expenses) income: | |||||||
Interest income | |||||||
997 | 456 | 425 | 270 | 315 | 243 | 187 | 242 |
Interest expense | |||||||
119 | 243 | 826 | 1,024 | 987 | 609 | 958 | 784 |
Other income (expenses), net | |||||||
59,389 | -1,516 | 2,919 | 8 | -2,794 | 201 | 508 | 1,023 |
Total non-operating (expenses) income, net | |||||||
60,267 | -1,303 | 2,518 | -746 | -3,466 | -165 | -263 | 481 |
Income (loss) before income taxes | |||||||
60,228 | -9,926 | 1,249 | 14,630 | -10,364 | -18,148 | 17,227 | 25,878 |
Income tax provision (benefit) | |||||||
13,723 | -3,266 | -2,398 | 4,810 | -7,577 | -7,449 | 5,365 | 7,784 |
Net income (loss) | |||||||
46,505 | -6,660 | 3,647 | 9,820 | - | - | - | - |
Net loss attributable to non-controlling interests | |||||||
-2,434 | -922 | - | - | - | - | - | - |
Net income (loss) attributable to Amphastar Pharmaceuticals, Inc. | |||||||
48,939 | -5,738 | 3,647 | 9,820 | -2,787 | -10,699 | 11,862 | 18,094 |
Net income (loss) per share attributable to Amphastar Pharmaceuticals, Inc. shareholders: | |||||||
Basic (in Dollars per share) | |||||||
1.04 | -0.12 | 0.08 | 0.22 | -0.06 | -0.25 | 0.31 | 0.47 |
Diluted (in Dollars per share) | |||||||
0.98 | -0.12 | 0.08 | 0.21 | -0.06 | -0.25 | 0.31 | 0.46 |
Weighted-average shares used to compute net income (loss) per share attributable to Amphastar Pharmaceuticals, Inc. shareholders: | |||||||
Basic (in Shares) | |||||||
46,982 | 46,395 | 46,107 | 45,375 | 44,961 | 41,957 | 38,712 | 38,580 |
Diluted (in Shares) | |||||||
49,907 | 46,395 | 48,367 | 47,504 | 44,961 | 41,957 | 38,883 | 38,940 |